AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17208410 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium enteric-coated delayed-release tablet (250mg)
Number of subjects: 15
Study 17208410 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (divalproex-ER) tablet (250mg)
Number of subjects: 15
Study 15223975 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified management (M) with flexible glycemic targets based on ultrasound measurements of Abdominal Circumference (AC) centile.
Number of subjects: 229
Study 15223975 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (C) with fixed glycemic targets.
Number of subjects: 229
Study 11454258 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis using Autopherese C
Number of subjects: 30
Study 11454258 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis using MCS3p
Number of subjects: 30
Study 10068743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 315
Study 10068743 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 315
Study 7518974 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 121
Study 7518974 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121
Study 2903874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million units over 1 hour)
Number of subjects: 17187
Study 2903874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin (160 mg/day for 1 month)
Number of subjects: 17187
Study 2903874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both streptokinase and aspirin
Number of subjects: 17187
Study 2903874 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase alone
Number of subjects: 17187
Study 2903874 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 17187
Study 2903874 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and aspirin
Number of subjects: 17187
Study 2903874 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17187
Study 2903874 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 17187
Study 2903874 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment
Number of subjects: 17187
Study 8314481 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (5 MU three times a week for 8 weeks, then 3 MU three times a week for 7 months)
Number of subjects: 48
Study 8314481 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 48
Study 8314481 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 48
Study 631642 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.12 microgram/min
Number of subjects: 0
Study 631642 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.25 microgram/min
Number of subjects: 0
Study 631642 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 4 microgram/min
Number of subjects: 0
Study 631642 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion (various doses)
Number of subjects: 0
Study 31094267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1073R-1-yogurt (100g every morning for 12 weeks)
Number of subjects: 96
Study 31094267 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (different Lactobacillus strain)
Number of subjects: 96
Study 28844118 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-216 (5-40 mg/kg)
Number of subjects: 48
Study 28844118 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-216
Number of subjects: 48
Study 28844118 — intervention group
Group type: COMPARATOR
Intervention: ETC-216
Number of subjects: 48
Study 28844118 — intervention group
Group type: COMPARATOR
Intervention: MDCO-216 vs ETC-216
Number of subjects: 48
Study 25805397 — intervention group
Group type: EXPERIMENTAL
Intervention: Soyabean oil
Number of subjects: 60
Study 25805397 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 60
Study 25805397 — intervention group
Group type: COMPARATOR
Intervention: Soyabean oil vs. Sunflower oil
Number of subjects: 60
Study 25805397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention arms
Number of subjects: 60
Study 23644901 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 16
Study 23644901 — intervention group
Group type: COMPARATOR
Intervention: No CPAP therapy (Control)
Number of subjects: 16
Study 21093107 — intervention group
Group type: EXPERIMENTAL
Intervention: Written handout added to verbal explanation
Number of subjects: 50
Study 21093107 — intervention group
Group type: COMPARATOR
Intervention: Verbal explanation only (Control)
Number of subjects: 50
Study 19470987 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized antidepressant therapy followed by a pain self-management program (12 weeks of therapy + 6 sessions of self-management over 12 weeks + 6 months continuation)
Number of subjects: 250
Study 19470987 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized antidepressant therapy followed by a pain self-management program
Number of subjects: 250
Study 17566453 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised circuit strength-training program (n=57)
Number of subjects: 83
Study 17566453 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised standard conditioning program (n=26)
Number of subjects: 83
Study 15502599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 to 60 mg/day
Number of subjects: 40
Study 15502599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11258693 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 175
Study 9754891 — intervention group
Group type: COMPARATOR
Intervention: Traditional basilic vein transposition (Group A)
Number of subjects: 40
Study 9754891 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged basilic vein transposition (Group B)
Number of subjects: 40
Study 8118531 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital delivery
Number of subjects: 59
Study 3367174 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation unit (GEU)
Number of subjects: 0
Study 3367174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31438903 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered over 17 weeks alongside enhanced usual care.
Number of subjects: 899
Study 31438903 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control arm).
Number of subjects: 899
Study 27255431 — intervention group
Group type: EXPERIMENTAL
Intervention: GL + sita (sitagliptin + insulin glargine)
Number of subjects: 65
Study 27255431 — intervention group
Group type: COMPARATOR
Intervention: NOV (premixed insulin aspart 30)
Number of subjects: 65
Study 25448109 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose IPV intramuscularly with needle and syringe
Number of subjects: 981
Study 25448109 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV intradermally administered with one of two new injectors
Number of subjects: 981
Study 25448109 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV administered with BCG needle
Number of subjects: 981
Study 25448109 — intervention group
Group type: EXPERIMENTAL
Intervention: fIPV administered with a conventional needle-free injector
Number of subjects: 981
Study 25448109 — intervention group
Group type: EXPERIMENTAL
Intervention: One of the two new injectors
Number of subjects: 981
Study 25448109 — intervention group
Group type: EXPERIMENTAL
Intervention: Other new injector
Number of subjects: 981
Study 23777741 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy
Number of subjects: 285
Study 23777741 — intervention group
Group type: COMPARATOR
Intervention: No axillary radiotherapy
Number of subjects: 285
Study 23777741 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy and No axillary radiotherapy (regardless of arm)
Number of subjects: 285
Study 23777741 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-positive and triple-negative subtypes
Number of subjects: 285
Study 23777741 — intervention group
Group type: EXPERIMENTAL
Intervention: High Ki67 cancers (≥14%)
Number of subjects: 285
Study 21829907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy combined with pharmacotherapy
Number of subjects: 41
Study 21829907 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 41
Study 19571281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PET-CT
Number of subjects: 189
Study 19571281 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 189
Study 16909131 — intervention group
Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA (Arm A)
Number of subjects: 379
Study 16909131 — intervention group
Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + inhaled‐IL‐2 (Arm B)
Number of subjects: 379
Study 16909131 — intervention group
Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + iv‐5‐FU (Arm C)
Number of subjects: 379
Study 16909131 — intervention group
Group type: EXPERIMENTAL
Intervention: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + po‐Capecitabine (Arm D)
Number of subjects: 379
Study 16909131 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Arm A and Arm B
Number of subjects: 379
Study 16909131 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Arm C and Arm D
Number of subjects: 379
Study 15261564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus beta interferon
Number of subjects: 225
Study 15261564 — intervention group
Group type: COMPARATOR
Intervention: Beta interferon alone
Number of subjects: 225
Study 11302007 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fish powder
Number of subjects: 0
Study 11302007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 tablets/day)
Number of subjects: 0
Study 8841501 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 31
Study 1623898 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/Codeine
Number of subjects: 16
Study 1623898 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine/Codeine
Number of subjects: 16
Study 1623898 — intervention group
Group type: COMPARATOR
Intervention: Quinidine/Placebo
Number of subjects: 16
Study 1623898 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Placebo
Number of subjects: 16
Study 6099262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 8
Study 6099262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 8
Study 6099262 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg)
Number of subjects: 8
Study 6099262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29524473 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy School Start intervention
Number of subjects: 29
Study 28463044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating-mesh nebulizer (VN)
Number of subjects: 6
Study 28463044 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 6
Study 25695403 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7123 50 mg
Number of subjects: 616
Study 25695403 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7123
Number of subjects: 616
Study 25695403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 24179013 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidative therapy (N-acetyl cysteine or MP865)
Number of subjects: 15
Study 24179013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24179013 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (CKD)
Number of subjects: 15
Study 24179013 — intervention group
Group type: COMPARATOR
Intervention: Controls (Healthy Subjects)
Number of subjects: 15
Study 21931024 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge to receive identical antibiotic treatment at home
Number of subjects: 117
Study 21931024 — intervention group
Group type: COMPARATOR
Intervention: Continued inpatient antibiotic therapy
Number of subjects: 117
Study 21931024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (home and hospital)
Number of subjects: 117
Study 19057627 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Number of subjects: 42
Study 19057627 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid
Number of subjects: 42
Study 16879461 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 7.5 mg alone
Number of subjects: 108
Study 16879461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 7.5 mg with 10 microg of fentanyl
Number of subjects: 108
Study 14753029 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nimesulid bd.
Number of subjects: 200
Study 14753029 — intervention group
Group type: COMPARATOR
Intervention: 275 mg naproxen bd.
Number of subjects: 200
Study 10067689 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-M vaccine
Number of subjects: 0
Study 7669532 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, multidisciplinary and integrated education programs
Number of subjects: 0
Study 7669532 — intervention group
Group type: COMPARATOR
Intervention: Baseline data from participating communities
Number of subjects: 0
Study 1975045 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2175
Study 1975045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2175
Study 1975045 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence (taking > 75% of prescribed medication)
Number of subjects: 2175
Study 7029004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose/electrolyte solution
Number of subjects: 61
Study 7029004 — intervention group
Group type: COMPARATOR
Intervention: Sugar/salt solution
Number of subjects: 61
Study 30961658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate as an adjunctive treatment
Number of subjects: 0
Study 30961658 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28535237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1-time or 2-time injection of 500 mg or 1000 mg according to body weight)
Number of subjects: 454
Study 28535237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 454
Study 28535237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 454
Study 26592217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Method
Number of subjects: 56
Study 26592217 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 56
Study 22552593 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace (moisture-tolerant sealant)
Number of subjects: 55
Study 22552593 — intervention group
Group type: COMPARATOR
Intervention: Helioseal (conventional sealant)
Number of subjects: 55
Study 22552593 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace
Number of subjects: 55
Study 22552593 — intervention group
Group type: COMPARATOR
Intervention: Helioseal
Number of subjects: 55
Study 21430302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health advisor (LHA) intervention consisting of two in-person visits, two phone calls, and four postcards.
Number of subjects: 286
Study 21430302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 286
Study 21430302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health advisor (LHA) intervention (self-report data).
Number of subjects: 286
Study 21430302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, self-report data).
Number of subjects: 286
Study 19203986 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50
Study 19203986 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 50
Study 17546385 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (20 cases)
Number of subjects: 38
Study 17546385 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 cases)
Number of subjects: 38
Study 15214901 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight shower or bath oils
Number of subjects: 0
Study 15214901 — intervention group
Group type: COMPARATOR
Intervention: Water (as a control)
Number of subjects: 0
Study 11802949 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (study group)
Number of subjects: 24
Study 11802949 — intervention group
Group type: COMPARATOR
Intervention: Invasive ventilation (control group)
Number of subjects: 24
Study 9588731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 50 mg/kg/day (maximum 2,000 mg/day)
Number of subjects: 69
Study 9588731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9306028 — intervention group
Group type: EXPERIMENTAL
Intervention: Eve 20 (20 micrograms ethinyl estradiol, 500 micrograms norethisterone)
Number of subjects: 118
Study 9306028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovelle (20 micrograms ethinyl estradiol, 150 micrograms desogestrel)
Number of subjects: 118
Study 2052798 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG vaccine
Number of subjects: 0
Study 7020775 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback group (EMG feedback from hip extensors)
Number of subjects: 25
Study 7020775 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-relaxation)
Number of subjects: 25
Study 7020775 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group (modified progressive relaxation)
Number of subjects: 25
Study 7020775 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback plus relaxation group (relaxation and EMG hip extensor feedback)
Number of subjects: 25
Study 31530444 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona pellucida-free blastocysts
Number of subjects: 419
Study 31530444 — intervention group
Group type: COMPARATOR
Intervention: Zona intact blastocysts (Control)
Number of subjects: 419
Study 28926295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg plaster
Number of subjects: 132
Study 28926295 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 132
Study 26079649 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - 12 months duration, heavy resistance exercises (5×10RM leg presses)
Number of subjects: 13
Study 26079649 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 13
Study 24134491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Functional Exercise (LiFE) program
Number of subjects: 150
Study 24134491 — intervention group
Group type: COMPARATOR
Intervention: Current exercise program (control)
Number of subjects: 150
Study 20621449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n = 169)
Number of subjects: 335
Study 20621449 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 166)
Number of subjects: 335
Study 20621449 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group differences
Number of subjects: 335
Study 18560816 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion-weighted magnetic resonance imaging (PW-MRI)
Number of subjects: 51
Study 18560816 — intervention group
Group type: COMPARATOR
Intervention: SAH patients with severe CVS
Number of subjects: 51
Study 18560816 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 51
Study 18560816 — intervention group
Group type: COMPARATOR
Intervention: SAH patients without CVS
Number of subjects: 51
Study 16555056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (L)
Number of subjects: 28
Study 16555056 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (I)
Number of subjects: 28
Study 16555056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (L+I)
Number of subjects: 28
Study 12951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) in preeclampsia group
Number of subjects: 440
Study 12951881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) in edema group
Number of subjects: 440
Study 12951881 — intervention group
Group type: COMPARATOR
Intervention: Bioelectrical impedance analysis (BIA) in control group
Number of subjects: 440
Study 12951881 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA as a predictor
Number of subjects: 440
Study 11284211 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 52
Study 11284211 — intervention group
Group type: COMPARATOR
Intervention: DTSQ(S)
Number of subjects: 52
Study 8728123 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of moderate dose (30 mg/d) beta‐carotene
Number of subjects: 20
Study 8728123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1678453 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 112
Study 1678453 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 112
Study 1678453 — intervention group
Group type: COMPARATOR
Intervention: ondansetron
Number of subjects: 112
Study 1678453 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone
Number of subjects: 112
Study 6136286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol 2 mg kg‐1 i.v. bolus injection
Number of subjects: 52
Study 6136286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol infusion (150 micrograms kg‐1 min‐1 for 30 min and 75 micrograms kg‐1 min‐1 thereafter)
Number of subjects: 52
Study 6136286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol alone
Number of subjects: 52
Study 6136286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol infusion
Number of subjects: 52
Study 31969177 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenezumab (300 mg subcutaneously every 2 weeks or 15 mg/kg, 30 mg/kg, 45 mg/kg, 60 mg/kg, or 120 mg/kg intravenously every 4 weeks)
Number of subjects: 131